Profile data is unavailable for this security.
About the company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
- Revenue in USD (TTM)0.00
- Net income in USD-31.48m
- Incorporated2007
- Employees9.00
- LocationForte Biosciences Inc3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS 75247United StatesUSA
- Phone+1 (310) 618-6994
- Fax+1 (302) 655-5049
- Websitehttps://www.fortebiorx.com/home/default.aspx
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lumos Pharma Inc | 2.05m | -34.03m | 24.35m | 33.00 | -- | 0.8902 | -- | 11.87 | -4.19 | -4.19 | 0.2526 | 3.37 | 0.0363 | -- | 9.47 | 62,151.52 | -60.27 | -29.78 | -68.62 | -32.32 | -- | -- | -1,659.39 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 25.03m | 298.00 | -- | 0.585 | -- | 0.5387 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 25.56m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Forte Biosciences Inc | 0.00 | -31.48m | 26.24m | 9.00 | -- | 0.7408 | -- | -- | -1.19 | -1.19 | 0.00 | 0.9719 | 0.00 | -- | -- | 0.00 | -77.74 | -72.06 | -84.92 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Lipocine Inc | -2.85m | -16.35m | 26.31m | 17.00 | -- | 1.28 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -38.37m | 26.32m | 14.00 | -- | -- | -- | -- | -2.96 | -2.96 | 0.00 | -0.4743 | 0.00 | -- | -- | 0.00 | -82.44 | -118.12 | -108.84 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.51 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Oncternal Therapeutics Inc | 785.00k | -39.48m | 26.64m | 27.00 | -- | 0.8829 | -- | 33.93 | -13.44 | -13.44 | 0.2672 | 10.19 | 0.0149 | -- | -- | 29,074.07 | -74.93 | -49.40 | -85.36 | -54.51 | -- | -- | -5,029.17 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| BioVie Inc | 0.00 | -43.27m | 26.72m | 18.00 | -- | 2.59 | -- | -- | -1.19 | -1.19 | 0.00 | 0.188 | 0.00 | -- | -- | 0.00 | -125.99 | -456.35 | -184.48 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.5764 | -- | -- | -- | -92.67 | -- | -- | -- |
| Unity Biotechnology Inc | 0.00 | -39.86m | 26.86m | 19.00 | -- | 0.9457 | -- | -- | -2.75 | -2.75 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -41.95 | -47.21 | -49.03 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Biora Therapeutics Inc | 4.00k | -124.33m | 26.96m | 58.00 | -- | -- | -- | 6,739.88 | -8.57 | -8.56 | 0.0003 | -4.28 | 0.00009 | -- | 0.0048 | 68.97 | -293.45 | -122.84 | -- | -369.01 | -- | -- | -3,108,350.00 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 27.73m | 32.00 | -- | 0.4287 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| Earth Science Tech Inc | 5.98m | 330.94k | 28.34m | 8.00 | 93.75 | 13.13 | 53.54 | 4.74 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -23.96m | 28.42m | 5.00 | -- | 2.39 | -- | -- | -1.50 | -1.50 | 0.00 | 0.7435 | 0.00 | -- | -- | 0.00 | -88.71 | -- | -102.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| America Great Health | 219.13k | -859.20k | 28.50m | 7.00 | -- | -- | -- | 130.07 | -0.00004 | -0.00004 | 0.00001 | -0.0002 | 0.6746 | 0.0721 | 18.16 | 31,304.29 | -265.62 | -543.96 | -- | -- | 95.92 | -247.36 | -393.74 | -1,193.55 | 0.035 | -1.37 | -- | -- | 95.23 | -- | 84.35 | -- | -- | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 28.56m | 7.00 | -- | 1.16 | -- | 48.97 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
Data as of May 07 2024. Currency figures normalised to Forte Biosciences Inc's reporting currency: US Dollar USD
54.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tybourne Capital Management (HK) Ltd.as of 31 Dec 2023 | 3.62m | 9.96% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 3.27m | 8.97% |
| BVF Partners LPas of 31 Dec 2023 | 2.98m | 8.19% |
| Cable Car Capital LLCas of 31 Dec 2023 | 2.03m | 5.58% |
| Fred Alger Management LLCas of 31 Dec 2023 | 1.84m | 5.05% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 1.81m | 4.97% |
| BML Capital Management LLCas of 31 Mar 2024 | 1.76m | 4.84% |
| Camac Partners LLCas of 03 Jan 2024 | 1.58m | 4.33% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 642.26k | 1.77% |
| Geode Capital Management LLCas of 31 Dec 2023 | 336.61k | 0.93% |
More ▼
Data from 31 Dec 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
